The role of Bruton's tyrosine kinase in pathogenesis of chronic spontaneous urticaria and the prospects for the use of new treatment
- Authors: Fedenko E.S.1, Elisyutina O.G.1,2, Ilina N.I.1
-
Affiliations:
- National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia
- Peoples’ Friendship University of Russia
- Issue: Vol 21, No 2 (2024)
- Pages: 265-282
- Section: Reviews
- URL: https://journals.rcsi.science/raj/article/view/260061
- DOI: https://doi.org/10.36691/RJA16941
- ID: 260061
Cite item
Abstract
Chronic spontaneous urticaria is a fairly common disease with an unpredictable course, burdensome symptoms and a significant negative impact on patients` quality of life. Despite the established stepwise approach to treatment with antihistamines in standard and increased dosages, anti-IgE therapy, there remains a portion of patients with unsatisfactory control of urticaria symptoms, with the need to develop drugs that target new therapeutic targets. Mast cells, basophils and B cells are key cells involved in the pathogenesis of urticaria; activation, differentiation, proliferation, cytokine secretion and degranulation in all three types of cells is regulated via Bruton's tyrosine kinase signalling pathway through FcεRI and BCR receptors respectively. Inhibition of Bruton's tyrosine kinase is being developed as a new therapeutic strategy for chronic spontaneous urticaria.
Here we present overview of the current understanding of chronic spontaneous urticarial`s pathogenesis, the role of Bruton's tyrosine kinase, the history of medical use of Bruton's tyrosine kinase inhibitors, as well as clinical data on the use of new Bruton's tyrosine kinase inhibitors in patients with chronic spontaneous urticaria who have not achieved adequate disease control with antihistamines.
Full Text
##article.viewOnOriginalSite##About the authors
Elena S. Fedenko
National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242
MD, Dr. Sci. (Med), Professor
Russian Federation, MoscowOlga G. Elisyutina
National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples’ Friendship University of Russia
Author for correspondence.
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894
MD, Dr. Sci. (Med)
Russian Federation, Moscow; MoscowNatalia I. Ilina
National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowReferences
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. EDN: YCCVNB doi: 10.1111/all.13397
- Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236. EDN: YLXKFV doi: 10.1111/bjd.19561
- Curto-Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticarial that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641–647. EDN: YJEFVJ doi: 10.2340/00015555-2941
- Melé-Ninot G, Serra-Baldrich E, Curto-Barredo L, et al. Definition of recurrent chronic spontaneous urticaria. Acta Derm Venereol. 2020;100(16):adv00267. doi: 10.2340/00015555-3633
- Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016. doi: 10.1111/all.13209
- Popova KY, Zaborova VA, Kurshev VV, et al. Clinical predictors of antihistamine resistance in patients with chronic spontaneous urticaria. Russ J Allergy. 2023;20(4):402–414. EDN: DIMFTH doi: 10.36691/RJA7951
- Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: 10.1111/bjd.14768
- Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020;50(10):1166–1175. EDN: ZTUTPO doi: 10.1111/cea.13716
- Kaplan A, Lebwohl M, Gimenez-Arnau AM, et al. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401. EDN: LFRXKZ doi: 10.1111/all.15603
- Konstantinou GN, Riedl MA, Valent P, et al. Urticaria and angioedema: Understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment. J Allergy Clin Immunol Pract. 2023;11(1):94–106. EDN: YUKJKQ doi: 10.1016/j.jaip.2022.11.006
- Kolkhir P, Gimenez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. doi: 10.1038/s41572-022-00389-z
- Alvarado D, Maurer M, Gedrich R, et al. The anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77(8):2393–2403. EDN: KVXABO doi: 10.1111/all.15262
- Kolkhir P, Elieh-Ali-Komi D, Metz M, et al. Understanding human mast cells: Lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022;22(5):294–308. EDN: OETTCH doi: 10.1038/s41577-021-00622-y
- Asero R, Marzano AV, Ferrucci S, et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200(3):242–249. EDN: JEUSWQ doi: 10.1111/cei.13428
- Xiang YK, Kolkhir P, Scheffel J, et al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. J Allergy Clin Immunol Pract. 2023;11(8):2417–2425.e1. EDN: XNPDRK doi: 10.1016/j.jaip.2023.02.006
- Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–882. EDN: YFVOAX doi: 10.1016/j.jaci.2017.10.035
- Cugno M, Asero R, Ferrucci S, et al. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria. Allergy. 2018;73(12):2408–2411. EDN: VHAZYR doi: 10.1111/all.13587
- Su H, Kolkhir P, Scheffel J, et al. One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2. Allergy. 2023;78(9):2537–2539. EDN: JGBWHQ doi: 10.1111/all.15734
- Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase: A novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. doi: 10.1371/journal.pone.0014794
- Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599–1604. doi: 10.1056/NEJM199306033282204
- Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996;106(5):1001–1006. doi: 10.1111/1523-1747.ep12338544
- Altrichter S, Zampeli V, Ellrich A, et al. IgM and IgA in addition to IgG autoantibodies against FcεRIα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020;75(12):3208–3215. EDN: KIJGPP doi: 10.1111/all.14412
- Jang JH, Moon J, Yang EM, et al. Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria. PLoS One. 2022;17(8):e0273415. EDN: LCLZXT doi: 10.1371/journal.pone.0273415
- Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol. 2022;(13):879754. EDN: VARNXK doi: 10.3389/fimmu.2022.879754
- Borzova EY. New aspects of the pathophysiology of chronic urticaria. Russ J Allergy. 2012;9(5):3–9. EDN: PEIQIN doi: 10.36691/RJA671
- Gimėnez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: The role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9(6):2195–2208. EDN: KYPUGA doi: 10.1016/j.jaip.2021.03.033
- Kishimoto I, Ma N, Takimoto-Ito R, et al. Decreased peripheral basophil counts in urticaria and mouse model of oxazolone-induced hypersensitivity, the latter suggesting basopenia reflectingmigration to skin. Front Immunol. 2022;(13):1014924. EDN: TAYEIZ doi: 10.3389/fimmu.2022.1014924
- Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: Diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003;33(3):337–341. EDN: BEUGQH doi: 10.1046/j.1365-2222.2003.01589.x
- Oliver ET, Sterba PM, Saini SS. Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria. Allergy. 2015;70(5):601–603. doi: 10.1111/all.12578
- Kern F, Lichtenstein LM. Defective histamine release in chronic urticaria. J Clin Invest. 1976;57(5):1369–1377. doi: 10.1172/JCI108405
- Oda Y, Fukunaga A, Washio K, et al. Low responsiveness of basophils via FcεRI reflects disease activity in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(8):2835–2844. EDN: YNSKBK doi: 10.1016/j.jaip.2019.05.020
- Lourenco FD, Azor MH, Santos JC, et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol. 2008;158(5):979–986. doi: 10.1111/j.1365-2133.2008.08499.x
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. EDN: NEWKMD doi: 10.1111/all.15090
- Steinweg SA, Gaspari AA. Rituximab for the treatment of recalcitrant chronic autoimmune urticaria. J Drugs Dermatol. 2015;14(12):1387.
- Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol. 2011;128(6):1354–1355. doi: 10.1016/j.jaci.2011.08.023
- Combalia A, Losno RA, Prieto-González S, Mascaró JM. Rituximab in refractory chronic spontaneous urticaria: An encouraging therapeutic approach. Skin Pharmacol Physiol. 2018;31(4):184–188. doi: 10.1159/000487402
- Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton’s tyrosine kinase inhibition: An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355–2366. doi: 10.1111/all.15261
- Neys SF, Hendriks RW, Corneth OB. Targeting Bruton’s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;(9):668131. doi: 10.3389/fcell.2021.668131
- Rip J, van der Ploeg EK, Hendriks RW, Corneth OB. The role of Bruton’s tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol. 2018;38(1):17–62. doi: 10.1615/CritRevImmunol.2018025184
- Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152(2):557–565.
- Weber AN, Bittner Z, Liu X, et al. Bruton’s tyrosine kinase: An emerging key player in innate immunity. Front Immunol. 2017;(8):1454. doi: 10.3389/fimmu.2017.01454
- Carnero Contentti E, Correale J. Current perspectives: Evidence to date on BTK inhibitors in the management of multiple sclerosis. Drug Des Devel Ther. 2022;(16):3473–3490. doi: 10.2147/DDDT.S348129
- Zhu S, Gokhale S, Jung J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets-beyond B lymphocytes. Front Cell Dev Biol. 2021;(9):727531. EDN: MQEUZR doi: 10.3389/fcell.2021.727531
- Alu A, Lei H, Han X, et al. BTK inhibitors in the treatment of haematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138. EDN: JLZNYD doi: 10.1186/s13045-022-01353-w
- Wahl MI, Fluckiger AC, Kato RM, et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors. Proc Natl Acad Sci USA. 1997;94(21):11526–11533. doi: 10.1073/pnas.94.21.11526
- Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilon RI. Nature. 1999;402(6760, Suppl):B24–В30. doi: 10.1038/35037021
- Bradshaw JM. The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal. 2010;22(8):1175–1184. doi: 10.1016/j.cellsig.2010.03.001
- Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996;271(5250):822–825. doi: 10.1126/science.271.5250.822
- Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, et al. Bruton’s tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials. Molecules. 2023;28(5):2400. doi: 10.3390/molecules28052400
- Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. doi: 10.1186/s12943-018-0779-z
- Satterthwaite AB, Li Z, Witte ON. Btk function in B cell development and response. Semin Immunol. 1998;10(4):309–316. doi: 10.1006/smim.1998.0123
- Khan WN, Sideras P, Rosen FS, Alt FW. The role of Bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;(764):27–38. doi: 10.1111/j.1749-6632.1995.tb55802.x
- McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton’s tyrosine kinase in the immune system and disease. Immunology. 2021;164(4):722–736. doi: 10.1111/imm.13416
- Rip J, de Bruijn MJ, Appelman MK, et al. Toll-like receptor signaling drives Btk-mediated autoimmune disease. Front Immunol. 2019;(10):95. doi: 10.3389/fimmu.2019.00095
- Kong W, Deng W, Sun Y, et al. Increased expression of Bruton’s tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol. 2018;37(1):43–49. doi: 10.1007/s10067-017-3717-3
- Corneth OB, Verstappen GM, Paulissen SM, et al. Enhanced Bruton’s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol. 2017;69(6):1313–1324. doi: 10.1002/art.40059
- Robak E, Robak T. Bruton’s kinase inhibitors for the treatment of immunological diseases: Current status and perspectives. J Clin Med. 2022;11(10):2807. doi: 10.3390/jcm11102807
- Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA. 2007;104(33):13283–13288. EDN: MMRISH doi: 10.1073/pnas.0702654104
- Kneidinger M, Schmidt U, Rix U, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008;111(6):3097–3107. doi: 10.1182/blood-2007-08-104372
- Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132(Suppl. 1):1871. doi: 10.1182/blood-2018-99-109973
- Regan JA, Cao Y, Dispenza MC, et al. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. J Allergy Clin Immunol. 2017;140(3):875–879. doi: 10.1016/j.jaci.2017.03.013
- Dispenza MC, Krier-Burris RA, Chhiba KD, et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J Clin Invest. 2020;130(9):4759–4770. doi: 10.1172/JCI138448
- Ellmeier W, Abramova A, Schebesta A. Tec family kinases: Regulation of FcεRI-mediated mast-cell activation. FEBS J. 2011;278(12):1990–2000. doi: 10.1111/j.1742-4658.2011.08073.x
- Suresh R, Dunnam C, Vaidya D, et al. The BTK inhibitor acalabrutinib reduces or eliminates clinical reactivity during oral challenge to peanut in allergic adults. J Allergy Clin Immunol. 2023;151(2):AB221. doi: 10.1016/j.jaci.2022.12.688
- MacGlashan DJ, Honigberg LA, Smith A, et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton’s tyrosine kinase, Btk, inhibitor. Int Immunopharmacol. 2011;11(4):475–479. doi: 10.1016/j.intimp.2010.12.018
- Smiljkovic D, Blatt K, Stefanzl G, et al. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. Allergy. 2017;72(11):1666–1676. doi: 10.1111/all.13166
- Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916
- Pulz R, Angst D, Eichlisberger D, Cenni B. Remibrutinib, a novel Bruton’s tyrosine kinase inhibitor, exhibits improved target selectivity and potency in vitro. EPO0896. Poster presented at: 38th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, October 26–28, 2022; Amsterdam, Netherlands; 2022.
- Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet. 2021;397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5
- Bender AT, Gardberg A, Pereira A, et al. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol Pharmacol. 2017;91(3):208–219. doi: 10.1124/mol.116.107037
- Crawford JJ, Johnson AR, Misner DL, et al. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J Med Chem. 2018;61(6):2227–2245. doi: 10.1021/acs.jmedchem.7b01712
- Langrish CL, Bradshaw JM, Francesco MR, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454–1468. doi: 10.4049/jimmunol.2001130
- Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756–1768. doi: 10.1111/cts.13005
- Herman AE, Chinn LW, Kotwal SG, et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor. Clin Pharmacol Ther. 2018;103(6):1020–1028. doi: 10.1002/cpt.1056
- Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: A randomized phase II trial. Nat Med. 2021;27(11):1961–1969. doi: 10.1038/s41591-021-01537-w
- Gimeno R, Ribas-Llauradó C, Pesque D, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticarial patients independently of FcεR1 expression level and omalizumab clinical response. Clin Transl Allergy. 2023;13(3):e12227. EDN: NRBQGZ doi: 10.1002/clt2.12227
- Ucpinar S, Smith PF, Long L, et al. Rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants. Clin Transl Sci. 2023;16(7):1210–1219. doi: 10.1111/cts.13524
- Maurer M, Berger W, Gimėnez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498–1506. doi: 10.1016/j.jaci.2022.08.027
- Jain V, Giménez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol. 2024;153(2):479–486.e4. doi: 10.1016/j.jaci.2023.10.007
- Carr W, Sitz K, Jain V, et al. Remibrutinib improves chronic spontaneous urticaria in patients irrespective of CU-index: Results from phase 2b study. Ann Allergy Asthma Immunol. 2022;129(Suppl. 5):S11. EDN: LSUIDJ doi: 10.1016/j.anai.2022.08.537
- Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–1915. doi: 10.1056/NEJMoa066092
- Katewa A, Wang Y, Hackney JA, et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNa-driven lupus nephritis. JCI Insight. 2017;2(7):e90111. doi: 10.1172/jci.insight.90111
- Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: A randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 2020;72(9):1435–1446. EDN: XSWFJF doi: 10.1002/art.41275
- Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73(10):1835–1846. doi: 10.1002/art.41811
- Bernstein JA, Maurer M, Saini SS. BTK signalling: A crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229–1240. EDN: HFXINM doi: 10.1016/j.jaci.2023.12.008
- Saini S, Giménez-Arnau A, Hide M, et al. Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies. Ann Allergy Asthma Immunol. 2023;131(5):S230. doi: 10.1016/j.anai.2023.10.019
- Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–780. doi: 10.1111/j.1398-9995.2008.01726.x
- Hawro T, Ohanyan T, Schoepke N, et al. Comparison and interpretability of the available urticaria activity scores. Allergy. 2017;73(1):251–255. doi: 10.1111/all.13271
- Maas A, Hendriks RW. Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol. 2001;8(3-4):171–181. doi: 10.1155/2001/28962
- Nyhoff LE, Clark ES, Barron BL, et al. Bruton’s tyrosine kinase is not essential for B cell survival beyond early developmental stages. J Immunol. 2018;200(7):2352–2361. doi: 10.4049/jimmunol.1701489
- Crofford LJ, Nyhoff LE, Sheehan JH, Kendall PL. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016;12(7):763–773. doi: 10.1586/1744666X.2016.1152888
- Nyhoff LE, Griffith AS, Clark ES, et al. Btk supports autoreactive B cell development and protects against apoptosis but is expendable for antigen presentation. J Immunol. 2021;207(12):2922–2932. doi: 10.4049/jimmunol.2000558
- Torke S, Pretzsch R, Häusler D, et al. Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020;140(4):535–548. doi: 10.1007/s00401-020-02204-z